Company intelligence / Profile preview

Curalogic

Ownership
Private
Development stage
Other
01

Overview

Curalogic developed oral immunotherapy products targeting allergic rhinitis, progressing key assets for grass, ragweed, and cat allergy to Phase 2, and house dust mite products to preclinical stage, before ceasing operations.

Therapeutic areas
Immunology
Modalities
ProteinBiologicExtract
Industry
Biotech
02

Drug pipeline

2 assets

microencapsulated grass pollen extract

1

1 more asset in the full pipeline.

03

Partnerships

Greer LaboratoriesSAFC (Sigma-Aldrich)

Beyond the preview

Go deeper on Curalogic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curalogic.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call